A population with rich connection to co-morbidities and events from more than 4,200 patients with end-stage renal disease

The biorepository service of DaVita Clinical Research® is unsurpassed in the industry, helping expand researchers’ knowledge and aiding in everything from development of intellectual property and proof of concept to drug discovery, novel diagnostic development and post-marketing safety surveillance.

  • Longitudinally-collected and clinical-trial quality blood, plasma, and serum samples
  • 4,200 patients enrolled
  • Accompanying data from electronic health records, claims, and patient-reported outcomes
  • A prospective collection vehicle with access to 950,000+ patients
  • A fully annotated repository of biospecimens that can provide deep clinical insights
  • The unique capabilities of a research organization within an integrated healthcare provider

Broad consent for many purposes and potential insights

The significance of our biorepository is that it’s fit-for-purpose, providing you with insights on biomarkers in pre-clinical to Phase III studies. Technological advances in genomic and proteomic sciences are increasing the value of biorepository use for potential application to a broad array of diagnostic and therapeutic targets. Application of our unique specimens may aid in:

  • Discovery, validation, and qualification of novel diagnostics and biomarkers
  • Identifying new indications for research compounds and marketed products
  • Streamlined clinical trial conduct: improved clinical trial design and efficiency, drug safety, attrition rate
  • Personalized medicine, companion or molecular diagnostics

Why biorepository samples from patients with renal disease?

Patients with ESRD are burdened with many comorbidites, many of which are available for study. The CDC is now redefining the risk factors and lowering diagnostic ranges for chronic kidney disease, and the anticipated rise in the rate of incidence for CKD will be similar to that of diabetes in the past 15 years.1

Technological advances in genomic and proteomic sciences are increasing the value of biorepositories for their potential application to a broad array of diagnostic and therapeutic targets. Application of our unique specimens may aid in:

  • Discovery, validation, qualification of novel diagnostics and biomarkers
  • Identifying new indications for research compounds and marketed products
  • Streamlined clinical trial conduct: improved clinical trial design and efficiency, drug safety, attrition rate
  • Personalized medicine, companion or molecular diagnostics

A population with rich connection to co-morbidities and events from more than 4,200 patients with end-stage renal disease

 

1. George L. Bakris and Eberhard Ritz, Hypertension and Kidney Disease, A Marriage that Should Be Prevented, Kidney International 75, 449-452 (13 February 2009)